Introduction
Atrial fibrillation (AF)-promoting atrial remodelling is induced by multiple stressors, including mechanical stretch and cytokine stimulation.
1,2 Atrial fibrosis, a major component of atrial structural remodelling, can be induced by AF per se. 3 In the fibrotic response, activated fibroblasts produce extracellular matrix (ECM) remodelling that negatively influences cardiac electrical, structural and contractile properties. 3, 4 A range of profibrotic signalling pathways has been implicated in myocardial fibrotic remodelling. Angiotensin II (Ang-II), transforming growth factor beta (TGF-b), and connective tissue growth factor (CTGF) are among the best-known. 3, [5] [6] [7] Mitogen-activated protein kinases (MAPKs) are important downstream effectors. 3, 8 Platelet-derived growth factor (PDGF) stimulates fibroblast proliferation and differentiation to myofibroblasts. 9 PDGF blockade reduces interstitial fibrosis of infarcted hearts in rats 10 and a PDGF inhibitor suppresses atrial-selective canine fibroblast activation, eliminating the characteristic atrial-ventricular fibroblast activation differences. 11 Limited information is available about the role of PDGF and associated signalling pathways in cardiac fibrosis and congestive heart failure (CHF). PDGF activates RAS-ERK1/2 or PI3K-Akt/mTOR pathways, promoting proliferation and protein synthesis in vascular smooth muscle cells. 12, 13 Signal transducer and activator of transcription 3 (STAT3), a latent transcription factor, is an important determinant of cell survival and proliferation. 14, 15 PDGF directly activates the Janus However, the contribution of the JAK-STAT system to atrial fibrosis and clinically relevant AF-substrates is unknown. In this study, we assessed the potential role of the PDGF-JAK-STAT system in regulating atrial fibroblast behaviour and atrial-selective fibrosis in CHF.
Methods

Animals
Animal-care procedures followed the guidelines of the Canadian Council on Animal Care and were approved by the Animals Research Ethics Committee of the Montreal Heart Institute. CHF was induced by ventricular tachypacing (VTP). VTP-dogs were anaesthetized under diazepam (0.25 mg/kg IV)/ketamine (5.0 mg/kg IV)/halothane (1-2% PI) anaesthesia, intubated, and ventilated. Bipolar pacing leads were fixed to the right-ventricular apex via left jugular-vein access, and connected to pacemakers (St Jude Medical, Minneapolis, MN) implanted subcutaneously in the neck. Following twenty-four hours for postoperative recovery, VTP was initiated at 240 bpm. Forty-seven adult mongrel dogs weighing 18.4-35.0 kg were divided into five groups: non-paced controls (n ¼ 17), 12-h VTP (n ¼ 5), 24-h VTP (n ¼ 5), 1-week VTP (n ¼ 5) and 2-week VTP (n ¼ 15). In a first series of dogs, we examined tissue protein expression, with five control dogs and five dogs euthanized after 2-week VTP. In a second series, we analysed gene expression in fibroblasts from 12 control dogs, and 5 each at 12 h, 24 h, and 1 week VTP, and 10 dogs at 2 weeks of VTP. AF-duration measurement and tissue procurement were obtained under morphine (2 mg/kg im)/alphachloralose (120 mg/kg iv) anaesthesia, with the heart exposed through a left thoracotomy. Further details of dog preparation and handling for the VTP-model are provided in the Supplementary material online. Twenty five male C57BL/6 mice (8-10 weeks) weighing 20-25 g (Charles River, Saint-Constant, Quebec) were divided into three groups:
MI was induced by left anterior descending coronary artery ligation (LAD), which was maintained for 2 weeks (methods detailed in the Supplementary material online). Vehicle (Sham and MI groups) or S3I-201 (10 mg/kg/d, MI þ S3I group) were delivered via osmotic mini-pumps (Alzet 2001; Cupertino, CA) implanted subcutaneously one day before surgery.
Echocardiography
Transthoracic echocardiographic studies under 2%-isoflurane were obtained before and 14 days after sham or MI surgery with a phased-array 10S probe (4.5-11.5 MHz) in a Vivid 7 Dimension System (GE Healthcare Ultrasound, Horten, Norway). Echocardiographic methods and measures are detailed in the Supplementary material online.
Tissue and cell harvesting
On study-days, dogs were anaesthetized with morphine (2 mg/kg s.c.) and alpha-chloralose (120 mg/kg i.v.) and mechanically ventilated. Dogs were then euthanized by cardiac excision. Their hearts were removed via median thoracotomy and immediately immersed in oxygenated Tyrode's solution. LA appendage, LA free wall and left ventricular (LV) free wall samples were fast-frozen in liquid-N 2 for molecular biology and/or stored in formalin for histology. LA and LV were perfused for cell isolation and collagenase digestion (see detailed description in Supplementary material online). Freshly isolated fibroblasts and cardiomyocytes were snap-frozen in liquid-N 2 and stored at -80 C.
Mice were deeply anaesthetized with isoflurane, then euthanized by cervical dislocation. Hearts were then excised, briefly washed in cold 0.9% saline solution and weighed. Left atria were fixed in 10% formalin at room temperature.
Cell-culture and treatment
Paired LA and LV cell-samples from each control dog were plated in 6-well plastic plates (Corning Inc., Corning, NY) in parallel at equal density and cultured in DMEM containing 5%-FBS and 1%-penicillin/streptomycin. Fibroblasts were allowed to adhere for 2 days, rendered quiescent in serum-free medium for 16 hours, and then stimulated with PDGF-AB (Sigma-Aldrich, St Louis, MO) at different concentrations (1-50 ng/ml) for 24 h (mRNA quantification) or 48 h (protein quantification). Cultured fibroblasts with PDGF-stimulation were treated with the JAK2-selective inhibitor AG-490 (Tyrphostin B42, Selleckchem, Houston, TX, 20 lM), the PDGF-receptor inhibitor tyrphostin AG-1296 (Selleckchem, 10 lM), the STAT3-inhibitor S3I-201 (Selleckchem, 20, 50, or 100lM) or the nonselective JAK-inhibitor filgotinib (GLPG0634, Selleckchem, 10, 100, or 1000 nM). DMSO-treated fibroblasts served as vehicle controls. Fibroblast number was counted by hemocytometer before plating and after treatment. Supernatants of culture media were collected from the treated cellcultures and fibroblasts were pelleted by centrifugation, followed by immediate freezing in liquid-N 2 for RNA or protein extraction. 
Protein extraction and immunoblots
Protein extracts (30-lg) of snap-frozen LA and LV tissue from dogs or cultured fibroblasts were separated by electrophoresis on 12% SDS-PAGE (Bio-Rad) and transferred to PVDF membranes (EMD Millipore, Billerica, MA). For secreted collagen type I, the supernatants of the media (32 ll) from cultured fibroblasts were separated by electrophoresis on 7.5% SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad). Membranes were blocked and incubated overnight with the primary antibodies and then with secondary antibodies. All of the details regarding antibodies are provided in the Supplementary material online.
Histology
LA appendage and LV free wall tissues from dogs and entire LAs from mice were preserved in 10% buffered formalin for paraffin embedment. 
Statistical analysis
Data are mean ± S.E.M. For non-repeated measurements, one-way ANOVA was used for multiple-group comparisons, with post-hoc Bonferroni-corrected t-tests (between two selected groups) or Dunnett's test (for comparisons between each intervention group and a single control group). For repeated measurements, two-way ANOVA with Bonferroni post-tests were used. When a significant interaction or main effect was found, pairwise comparisons were performed with Bonferroni-corrected t-tests. Statistical analyses were performed with GraphPad v5.0 (La Jolla, CA). A two-tailed P < 0.05 was considered statistically significant.
Results
PDGF/JAK-STAT pathway activation in experimental CHF
CHF dogs developed progressive AF susceptibility and atrial fibrosis. AF duration increased significantly from 1-week VTP and atrial-predominant Figure S1 ), consistent with previous work. 3, 11 The baseline expression levels of PDGFC and PDGFD in atrial fibroblasts were greater than those in ventricular (Supplementary material online, Figure S2A ). Fibroblast-selective expression (versus cardiomyocytes) was observed for PDGFB, PDGFC (in LA), and PDGFD. In particular, PDGFD expression was 10-fold higher in LA fibroblasts compared with LA cardiomyocytes (Supplementary material online, Figure S2A ). mRNA expression of PDGFA, PDGFC, and PDGFD was upregulated in atrial fibroblasts from CHF dogs, whereas PDGFB did not change significantly ( Figure 1A-D) . No significant alterations were seen in ventricular fibroblasts, other than an isolated increase in PDGFC at 12-hour VTP ( Figure 1A-D) . In summary, PDGF isoforms showed fibroblast-selective expression at baseline and atrial-selective increases in CHF fibroblasts at time-points corresponding to in vivo AF-promotion and LA-selective fibrosis development. As PDGF is a secreted protein, we did not perform tissue Western blots.
PDGF receptor a (PDGFRa) and PDGF receptor b (PDGFR b) transcripts were predominantly expressed in fibroblasts compared with cardiomyocytes in both LA and LV (Supplementary material on line, Figure S2B ). Small, statistically non-significant changes (with the exception of a weakly significant PDGFRa decrease in LA at 2-week VTP) in mRNA expression of PDGFRa and PDGFR b occurred with CHF ( Figure 1E and F). Protein expression of PDGFRa in LA-tissue was higher than in LV. However, no significant differences were seen between control and fully developed CHF (2-week VTP; Figure 1G ). PDGFRb showed similar expression levels in control LA versus LV and was increased by CHF in LA (but not LV, Figure 1H ). The PDGF and PDGFRb expression data suggest the involvement of PDGF in atrial-selective fibrogenesis with CHF.
The expression levels of the downstream effectors of PDGF signalling, JAK1/2 and STAT3, in control and CHF fibroblasts are shown in Figure 2 . The mRNA expression of JAK1 did not change significantly with CHF Mean ± S.E.M., n ¼ 5-12/group, *P < 0.05, **P < 0.01, vs. CTL. (C) Representative immunoblots for phosphorylated STAT3 (p-STAT3) and t-STAT3 from atrial and ventricular tissue. (D-F) Band-intensities for p-STAT3, t-STAT3 (normalized to GAPDH), and phosphorylated-STAT3/t-STAT3 ratio. Mean ± S.E.M., n ¼ 5/group, *P < 0.05, **P < 0.01, ***P < 0.001. One-way ANOVA with Dunnett's tests (A and B) or Bonferroni-corrected t-tests (D-F) were used for statistical analysis. FB, fibroblast; LA, left atrial; LV, left ventricular; CTL, non-paced controls; CTL-A, control atrium; CTL-V, control ventricle; CHF-A, congestive heart failure atrium; CHF-V, congestive heart failure ventricle. Figure 2A ). JAK2 expression, however, was upregulated with significant changes beginning at 1-week VTP, and similar changes in LA and LV fibroblasts ( Figure 2B ). We were unable to perform successful Western blots for JAK 1 and 2, because the commercially available antibodies (all raised against non-canine epitopes) proved to be inadequate. Proteinexpression of phosphorylated and total STAT3 (t-STAT3) were increased by CHF in both LA and LV ( Figures 2C-E) . The ratio of phosphorylated-STAT3 to total-STAT3 was significantly upregulated, indicating STAT3 activation, in LA but not LV tissue ( Figure 2F) . A twofold greater expression of JAK2 was seen in fibroblasts vs. cardiomyocytes (Supplementary material online, Figure S2C ), but the baseline expression of STAT3 was similar in fibroblasts and cardiomyocytes. In all, our results show that PDGFA/C/D, PDGFRb, JAK2, and phosphorylated-STAT3 are upregulated in CHF-dogs, and that the changes are atrial-selective.
JAK-STAT pathway activation and ECM production changes in fibroblasts after PDGF-stimulation
Our results indicate LA-selective enhancement of the expression of PDGF and its b-receptor isoform in CHF. It is tempting to speculate that the PDGF changes are responsible for the JAK-STAT activation that we noted. In order to study the potential effects of the PDGFsystem on cardiac fibroblast function and JAK-STAT signalling, freshly isolated fibroblasts from control dogs were cultured and exposed to recombinant PDGF-AB. PDGF-AB caused an augmentation of mRNAexpression of PDGFRa and PDGFRb ( Figure 3A and B) . The proteinexpression of PDGFRa increased with PDGF-AB exposure ( Figure 3C  and D) , showing preferential responses in LA versus LV at low concentrations (note that effects are shown as fold-changes relative to vehicle-control).
PDGF increased the mRNA-expression of JAK2 significantly, to a similar level in LA and LV fibroblasts ( Figure 4A) , consistent with the increases in JAK2-expression in both LA and LV fibroblasts with CHF ( Figure 2B ). PDGF increased mRNA expression of STAT3 significantly in LA fibroblasts, without significant changes in LV fibroblasts ( Figure 4B ). Phosphorylated-STAT3/total-STAT3 ratio increased significantly in LA fibroblasts by 4.2-fold at 5 ng/ml and 5-fold at 10 ng/ml PDGF vs. vehicle ( Figure 4C and D) . There were no significant changes in LV fibroblasts at either concentration. These results confirm the ability of PDGF to activate the JAK-STAT system in atrial fibroblasts. PDGF-stimulation increased the cell number by 2.2-fold in LA fibroblasts, and by 1.9-fold in LV fibroblasts (Supplementary material online, Figure S3 ). Fibroblast secretion of collagen type I (Collagen-1) into the culture supernatant was increased by PDGF-stimulation in LA fibroblasts; however, no statistically significant changes were seen in LV fibroblasts ( Figure 4E and F) . Fibronectin-1 secretion increased in a dose-dependent manner with PDGF-stimulation, and greater changes were seen in LA vs. LV fibroblasts ( Figure 4G and H).
Effects of JAK-inhibitors on results of PDGF-stimulation in fibroblasts
The actions of PDGF-stimulation to increase the expression of phosphorylated-STAT3 and phosphorylated-STAT3/total-STAT3 ratio in atrial fibroblasts were abolished by the JAK2-selective inhibitor AG-490 or the PDGF-receptor inhibitor AG 1296 ( Figure 5A-D) . Similarly, PDGF-upregulation of fibroblast proliferation and collagen-1 secretion was reversed by treatment with AG-490 or AG 1296 ( Figure 5E-G) . These results show that JAK2 is involved in the downstream signalling Figure S4) . However, at 100 and 1000 nM, the drug substantially attenuated PDGF effects on STAT3 phosphorylation and fibroblast function. These results suggest that JAK1 is unlikely to contribute to JAK/STAT signalling downstream to PDGF.
Effects of the STAT3 inhibitor S3I-201 on PDGF-stimulation of fibroblasts
The mRNA expression-levels of STAT3, collagen-1a1, and collagen 3a1 in the presence of PDGF-stimulation were all reduced by S3I-201 treatment in a dose-dependent manner ( Figure 6A-C) . The effect of PDGF-stimulation on phosphorylated-STAT3 was reversed by S3I-201-treatment, while S3I-201 did not affect the expression level of total-STAT3 ( Figure 6D) , so that the PDGF-induced increase in the ratio of phosphorylated-STAT3 to total-STAT3 was suppressed by S3I-201 ( Figure 6E) . Furthermore, S3I-201 reversed the augmentation in collagen-1 secretion caused by PDGF-stimulation (Figure 6F 
Effects of S3I-201 in mice with post-MI LV dysfunction
Mice studied 2 weeks post-MI showed LV hypertrophy manifested as increased heart weight and increased LV mass/body-weight ratio (black bars in Supplementary material online, Figure S5A and B). Their LVs were dilated (Supplementary material online, Figure S5C and D) and showed significant functional impairment (Supplementary material online, Figure  S5E -H). Considerable LA fibrosis was noted ( Figure 7A and B) and electrocardiographic P-wave durations were prolonged ( Figure 7C ), indicating LA conduction abnormalities. The LA was dilated in LV systole and diastole ( Figure 7D and E). These results indicate significant LA-disease due to LV dysfunction post-MI. The effects of the STAT3 blocker S3I-201 are illustrated in Figure 7 and Supplementary material online, Figure S5 . S3I-201 did not significantly alter post-MI LV remodelling and dysfunction (Supplementary material online, Figure S5 ). However, adverse LA remodelling post-MI was significantly attenuated, with nearly complete reversal of changes in LA fibrous-tissue content and P-wave duration ( Figure 7A-C) . LA dilation was modestly but significantly attenuated when measured at LV end-systole ( Figure 7D ), but not significantly altered at end-diastole ( Figure 7E) . Overall, these results indicate an important role of the JAK-STAT system in LA structural remodelling due to LV dysfunction in a clinically relevant in vivo model.
Discussion
This study provides new insights into the role of PDGF/JAK-STAT signalling in the fibrotic process leading to the AF-substrate in CHF. Our findings are summarized schematically in Figure 8 . We found upregulation of key components of the PDGF/JAK-STAT pathway in CHF-related atrial fibrotic remodelling ( Figure 8, red arrows) . We noted that PDGFstimulation of atrial fibroblasts up-regulated JAK-STAT expression and activity, and enhanced ECM-protein production (Figure 8 blue arrows) . The profibrotic cellular effects of PDGF were attenuated by the PDGFreceptor inhibitor AG 1296 ( Figure 8 , orange symbols), the JAK2-selective inhibitor AG-490, the JAK-inhibitor filgotinib at concentrations that inhibit JAK2 (Figure 8, grey symbols) , and the STAT3 inhibitor S3I-201 ( Figure 8, green symbols) . Finally, we showed that in vivo administration of S3I-201 reduces atrial structural, electrical, and fibrotic remodelling in mice with LV-dysfunction post-MI. Our results suggest that the JAK-STAT pathway plays a potentially important role in the atrial fibrosis associated with AF-promoting LV-dysfunction.
JAK-STAT in cardiac remodelling
Mechanical stretch, pressure overload, 21 MI, 22 and Ang-II treatment 23 activate cardiac JAK-STAT signalling. JAK-STAT activation enhances cardiomyocyte survival and reduces apoptosis by regulating the expression of multiple cardioprotective, anti-inflammatory, or growth-related genes. 14 The activation of STAT3 during early heart-failure might be a protective response, 14 and cardiomyocyte-specific STAT3 knockout mice show enhanced susceptibility to cardiac injury. 24 IL-10 and IL-11 attenuate cardiac dysfunction, preventing apoptotic cell death and reducing inflammation, by activating STAT3. 22, 25 On the other hand, JAK-STAT signalling activated by IL-1b and Ang-II leads to cardiomyocyte hypertrophy in vitro and in the mouse heart with pressure-overload. 26 ,27 S3I-201 protects against Ang-II induced oxidative stress, endothelial dysfunction and hypertension in rats. 28 In the present study, S3I-210 attenuated atrial enlargement in mice with LV-dysfunction 2 weeks post-MI, but did not significantly affect ventricular remodelling. Most studies analysing the effects of JAK-STAT signalling on cardiac cells have been performed in cardiomyocytes, with much less known about JAK-STAT actions in cardiac fibroblasts. JAK-STAT activation was found to correlate with early cell trans-differentiation, proliferation, and differentiation of fibroblasts in human hepatic and cutaneous scar tissue. 29, 30 Bowman et al. 18 pointed out the importance of PDGF-Src-Stat3-Myc signalling in PDGF-induced mitogenesis of NIH 3T3 fibroblasts. Tsai et al.
31
found that Ang-II activates STAT3 via Rac1 in atrial cardiomyocytes and fibroblasts. In this study, we noted PDGF/JAK-STAT activation in CHFinduced atrial remodelling and demonstrated that the fibroblast-activating effects of PDGF to enhance proliferation and ECM-protein production are mediated through JAK-STAT activation. JAK-STAT activation was atrialselective, consistent with the greater degree of fibrosis in LA versus LV (Supplementary material online, Figure S1 ), and was also selective for fibroblasts over cardiomyocytes. Our findings indicate that the JAK-STAT system is an important regulator of atrial fibroblast behaviour.
JAK-STAT in atrial fibrosis associated with AF
Tsai et al. 19 showed that STAT1 and STAT3 were both activated in pigs with pacing-inducing sustained AF. Xue et al. 32 showed that STAT3 protein expression was increased in atrial tissue from permanent AF patients with rheumatic heart disease compared with those in sinus rhythm, paralleling changes in atrial fibrous tissue content. Neither study addressed the role of STAT3-activation by blocking the system in vivo. Our finding that STAT3 inhibition reduces atrial fibrosis associated with LVdysfunction in post-MI mice indicates the functional importance of STAT3-change in AF. This result is consistent with observations that STAT3 inhibition has anti-fibrotic effects in other systems. For example, Pang et al. 33 showed that inhibition of STAT3 attenuates renal interstitial fibroblast-activation and interstitial fibrosis in obstructive nephropathy. Mir et al. 34 noted that inhibition of STAT3 attenuates collagen synthesis and hypertrophy in a rat cardiac hypertrophy model.
Novelty and potential significance
To the best of our knowledge, this is the first study to elucidate the role of the JAK-STAT system in AF-promoting atrial fibrotic remodelling.
Although the JAK-STAT system is indicated in schemas of potential profibrotic pathways in AF, 2 the pathway has not previously been directly addressed in studies of atrial profibrillatory fibrotic remodelling. JAK-STAT signalling can be activated downstream to either Ang-II or PDGF receptors; the present study points to PDGF as an important component of the atrial profibrotic JAK-STAT axis. This is also the first study to demonstrate atrial-selective activation of the PDGF/JAK-STAT system in cardiac remodelling. In addition to PDGF, various other profibrotic pathways, such as those mediated via Ang-II, IL-6, and CTGF, can involve the participation of JAK-STAT. 29, 31 Ang-II activates JAK-STAT through Rac1 in rat fibroblasts, 31 and CTGF induces JAK-STAT activation in human hypertrophic scar fibroblasts.
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JAK2 activation also leads to the phosphorylation of other proteins such as MAPKs. 35 In addition, JAK-STAT signalling represents one limb of an autocrine loop for Ang-II generation, which serves to amplify the action of Ang-II in cardiac remodelling. 36 Therefore, the JAK-STAT system is well positioned to serve as a central mediator in fibrotic responses and contribute to atrial remodelling. Although PDGF is secreted by both fibroblasts and cardiomyocytes, PDGF receptors are predominantly expressed in fibroblasts (Supplementary material online, Figure S2B) . Thus, the PDGF/JAK-STAT system is a potential target for fibroblast-selective treatment. PDGF-receptor inhibitors attenuate fibrosis in multiple studies 10, 37, 38 and suppress atrial-selective cardiac fibroblast activation. 11 However, most PDGFR inhibitors are non-selective tyrosine kinase inhibitors, limiting their clinical use. Therefore, the identification of JAK-STAT as an alternative target, and the development of JAK-STAT inhibitors like S3I-201, may point to novel therapeutic approaches for AFprevention.
Potential limitations
It has been shown that during myocardial fibrosis in salt-sensitive hypertensive rats, PDGFRa acts at early stages, but PDGFRb function is enhanced throughout the remodelling process. 9 This might explain why we observed upregulation of PDGFRb protein in CHF but no changes in PDGFRa ( Figure 1G and H), as we analysed tissue samples from dogs with 2-week VTP only because of a lack of protein-sample availability from earlier time-points. In addition, whereas PDGFRb protein increased Figure 1H) , PDGFRB mRNA did not change significantly ( Figure 1F) . This discrepancy between mRNA and protein results may be due to post-transcriptional regulation (e.g. by microRNA).
In this study, we focused on changes in fibroblasts since we were interested in the role of the JAK-STAT system in profibrillatory fibrotic remodelling. We did study the evolution of JAK2 and STAT3 mRNA expression over VTP time in cardiomyocytes from CHF dogs. As shown in Supplementary material online, Figure S6 , the only change we saw was an isolated increase in STAT3 expression at 12-h VTP. However, a detailed exploration of possible JAK-STAT changes in CHF cardiomyocytes and its importance is beyond the scope of this study. Similarly, it is possible that JAK-STAT signalling involves downstream pathways additional to those that we examined here. Atrial fibrosis is known to play an important role in AF pathophysiology, particularly in the model we studied here, 3, 5 but JAK-STAT signalling could also be acting via the regulation of cardiomyocyte ion channels or Ca 2þ handling.
The mouse studies were conducted as a proof of principle for the involvement of STAT3-signalling in atrial fibrosis associated with myocardial dysfunction. Because of the small size of mouse atria, all of the LA tissue samples from mice were used for Masson Trichrome staining ( Figure 7A ). We did have limited right-atrial tissue samples on which we performed Western blots for PDGFRa, PDGFRb, STAT3 and phosphorylated-STAT3. The PDGFR changes were in qualitative agreement with the dog data but no statistically significant differences were seen (Supplementary material online, Figure S7) , and the STAT3 data showed no consistent trends (Supplementary material online, Figure S8 ). The discrepancies from our dog data may be due to the fact that the mouse work was performed in right atrium, which may be much less affected by MI than LA, and/or to species differences in relative contributions of fibroblasts versus cardiomyocytes to atrial-tissue expression of PDGFRs and STAT3. Since fibroblasts comprise only a small part of the myocardial mass, contamination by other cell types could account for the lack of consistent changes. We did not have fibroblast samples from the intervention study in the mice, and even if we repeated the full experimental series the quantity of freshly isolated fibroblasts from the very small mouse atrium would not have been enough to perform Western blots.
The role of atrial JAK-STAT signalling pathways in CHF patients remains to be investigated. We were unable to perform such studies because of a lack of human atrial samples from patients with CHF, but we hope to investigate this issue in future work.
STAT3 regulates a broad range of genes controlling cell survival, cell cycle progression, inflammation, ECM homeostasis and cell-to-cell communication. Thus, STAT3-inhibition may have significant extra-cardiac effects on other cell types and organs; thus, systemic STAT3 inhibition might not be a viable anti-AF strategy because of adverse effect potential. 39 No toxic effects of STAT3 inhibition were seen in MI mice of our study, or reported in other animal models of cardiac hypertrophy or tissue fibrosis. 40, 41 However, the safety profile of STAT3 inhibition in other animal models and with longer term administration remains to be assessed. Heart-specific or cardiac fibroblast-targeting STAT3-inhibition, e.g. by cardiac-directed biological therapy, might be a possible approach to achieve efficacy without unwanted effects. Although we demonstrated that STAT3 activation causes fibroblast proliferation and increases ECM production, we did not study the downstream mechanisms of STAT3 fibroblast regulation. Further work is thus needed to identify the range of STAT-responsive genes and signalling pathways responsible for the contribution of STAT3 to atrial fibrogenesis. Although S3I-201 is a widely used JAK-STAT inhibitor, like all pharmacological agents there are concerns about specificity. It would be of interest to use mice with genetically inactivated JAK-STAT signalling to test our hypothesis. Systemic genetic knockdown of STAT3 might produce indirect effects mediated by JAK-STAT ventricular cardiomyocyte signalling. In vivo inducible genetic inhibition of STAT3 in atrial fibroblasts would be of great interest but is technically challenging and out of the scope of this study.
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